What this is
- How it works
- How it works isn't classified yet
- Tested for
- Rhinovirus Infection
- Main trialPhase 2
- “Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the severity and/or duration of respiratory symptoms associated with RV infections in patients with COPD.”In the company’s words, NCT07610395 on ClinicalTrials.gov
- Other names
- Vapendaivr
Coming up1
- 15 Nov 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 15 Nov 2027 | Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD | |
| Phase 2Completed | 30 Mar 2025 | RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection | |
| Phase 1/2Completed | 23 Mar 2025 | A Study to Evaluate Metabolism, Excretion, and Mass Balance of [14C]Vapendavir | |
| Phase 1Completed | 12 Dec 2023 | Phase 1 Study Into Pharmacokinetics and Food Effect of Vapendavir in Healthy Participants and Participants With COPD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026